Trial Details
COMPLETEDBasic Information
| Clinical ID | c2123 |
|---|---|
| Identifier | NCT03945019 |
| Trial Title | CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | BIOLOGICAL: CT-P13 SC (Infliximab)|OTHER: Placebo SC |
Participant Information
| Sponsor | Celltrion |
|---|---|
| City | Houston |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2019-10-28 |
|---|---|
| Primary Completion Date | 2022-08-23 |
| Completion Date | 2023-08-22 |